clazakizumab
Term · Oncology and biomedicine · MLC-T-ONC-012631
A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (Il-6) with potential immunomodulating activity. Upon administration, clazakizumab binds to and blocks the activity of IL-6, which may mitigate the catabolic effects of IL-6.
| Identifier | MLC-T-ONC-012631 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-IL6 monoclonal antibody ALD518 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012631",
"term": "clazakizumab",
"field": "Oncology and biomedicine",
"definition": "A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (Il-6) with potential immunomodulating activity. Upon administration, clazakizumab binds to and blocks the activity of IL-6, which may mitigate the catabolic effects of IL-6.",
"synonyms": [
"anti-IL6 monoclonal antibody ALD518"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/clazakizumab/"
}
Record 4,930 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.